Drug & Toxic Injury
Personal Injury
Asbestos
Class Actions
Securities Fraud
Commercial Litigation
Gulf Oil Spill
Yaz, Yasmin, and Ocella
Accutane
Hydroxycut
Accutane News Roundup
The news articles rolled in after Seeger Weiss secured an enormous victory for a victim of Accutane.
Associated Press (via ABC): “NJ Jury Awards $25M to Ala. Man in Accutane Suit”
A New Jersey jury has hit the pharmaceutical company that makes Accutane with a $25.16 million judgment…
National Law Journal – “This Time Roche’s Loss to Accutane Suit Is Big, Real Big”
“This drug is awful, and the warnings were inadequate. [Roche] warned about things like pregnancy and those problems, but everything else they really ignored,” said Christopher Seeger of New York’s Seeger Weiss, one of four plaintiffs’ firms that is handling the scores of Accutane lawsuits. The others are Hook Bolton, Beggs & Lane, and Levin Papantonio — all in Pensacola, Fla.
New Jersey Law Journal – “In Retrial, N.J. Jury Awards $25 Million to Accutane User”
David Buchanan of Seeger Weiss in New York, one of the plaintiffs lawyers, says the reversal disappointed him at the time, but he was buoyed by the affirmance of Higbee’s other rulings. As a result, he says, the appeals court “provided a blueprint that will be useful in other trials.”
Buchanan says it is impossible to say for certain why the second jury returned so magnified a verdict after hearing the defense evidence the judge excluded at the first trial.
Two possible explanations: First, the first jury’s damage finding was lower than it should have been. “McCarrell’s case is one of the most serious,” he says. Second, the experience of the first trial has improved the plaintiffs lawyers’ presentations. “We’re getting better,” he says.
Buchanan says Tuesday’s verdict should send a message to the company that a settlement of pending cases would be wise. “I would hope they would acknowledge what the juries are telling them. I am hoping the message is heard.”
Law360 – “Roche Hit With $25M Accutane Verdict”
The nine-member jury found that Roche failed to provide an adequate warning to McCarrell’s prescribing physician about the risks of inflammatory bowel disease from Accutane and that that failure to warn was a “proximate cause” of McCarrell’s IBD, according to McCarrell’s lawyers.
Subscribe to our RSS